Rachel Klemovitch, Assistant Editor02.26.24
Israeli-based technology company, MAGENTIQ-EYE, announced the publication of a comprehensive study on the performance of its MAGNTIQ-COLO in the Lancet Digital Health medical journal.
The study took place over 14 months across 10 leading medical centers with 952 screened and enrolled patients and 31 endoscopists.
According to the study, MAGENTIQ-COLO increased the adenoma detection rate (ADR) by 7% in absolute values. The decrease in colorectal cancer (CRC) occurrence and patient mortality is believed to have a strong connection to increased ADR.
The study also measured the impact of MAGENTIQ-COLO on adenoma miss rate (AMR); showing that with MAGENTIQ-COLO, AMR was 17% lower in absolute values.
This research validates MAGENTIQ-COLO at the highest level of performance in the AI-aided colonoscopy category.
“We are honored to be published by Lancet Digital Health, a journal with a phenomenal worldwide reputation for circulating innovative, practice-changing research,” said MAGENTIQ EYE founder and CEO, Dror Zur. “It is important to note that measuring changes in both ADR and AMR in a single study is a novelty. In addition to FDA approval that we received last year, this milestone is a testament to the impact of MAGENTIQ-COLO™ in advancing the quality of colonoscopy and setting new healthcare standards in order to save more and more lives.”
The U.S. National Institutes of Health ranks CRC as the nation’s third-leading cause of cancer-related deaths. CRC typically originates from polyps or other precancerous growths in the colon or rectum that can be detected in a colonoscopy.
Despite standard colonoscopy practices in most developed countries, high missed rates and undetected adenoma lead to a risk of developing colon cancer even in those who are tested regularly.
MAGENTIQ-COLO is currently marketed in the US and Europe.
The study took place over 14 months across 10 leading medical centers with 952 screened and enrolled patients and 31 endoscopists.
According to the study, MAGENTIQ-COLO increased the adenoma detection rate (ADR) by 7% in absolute values. The decrease in colorectal cancer (CRC) occurrence and patient mortality is believed to have a strong connection to increased ADR.
The study also measured the impact of MAGENTIQ-COLO on adenoma miss rate (AMR); showing that with MAGENTIQ-COLO, AMR was 17% lower in absolute values.
This research validates MAGENTIQ-COLO at the highest level of performance in the AI-aided colonoscopy category.
“We are honored to be published by Lancet Digital Health, a journal with a phenomenal worldwide reputation for circulating innovative, practice-changing research,” said MAGENTIQ EYE founder and CEO, Dror Zur. “It is important to note that measuring changes in both ADR and AMR in a single study is a novelty. In addition to FDA approval that we received last year, this milestone is a testament to the impact of MAGENTIQ-COLO™ in advancing the quality of colonoscopy and setting new healthcare standards in order to save more and more lives.”
The U.S. National Institutes of Health ranks CRC as the nation’s third-leading cause of cancer-related deaths. CRC typically originates from polyps or other precancerous growths in the colon or rectum that can be detected in a colonoscopy.
Despite standard colonoscopy practices in most developed countries, high missed rates and undetected adenoma lead to a risk of developing colon cancer even in those who are tested regularly.
MAGENTIQ-COLO is currently marketed in the US and Europe.